All Articles
Psychedelics

Lykos Therapeutics Launches With $100 Million For MDMA Treatments

January 7, 2024
x min read
Lykos Therapeutics Launches With $100 Million For MDMA Treatments

The most important non profit organization in the history of psychedelics has just launched their first ever for profit biotechnology company.

What’s happening:

  • The Multidisciplinary Association for Psychedelic Studies, most commonly referred to as MAPS, has officially launched Lykos Therapeutics as a for profit biotechnology company to advance MDMA assisted therapies
  • Lykos Therapeutics, which was formerly known as MAPS Public Benefit Corporation and previously wholly owned by MAPS, has raised $100M USD in a Series A round led by Helena, with participation from billionaire Steve Cohen’s family foundation, True Ventures and Satori Neuro

Why it matters:

  • For decades, MAPS has been leading the psychedelic renaissance through their scientific research and advocacy efforts to attempt to make psychedelic compounds accessible to patients
  • MAPS Public Benefit Corporation has been the longstanding leader in psychedelic science through their groundbreaking Phase III clinical trial of MDMA for the treatment of Post Traumatic Stress Disorder
  • Launching Lykos Therapeutics as a for profit biotechnology company marks a potentially pivotal turning point for the future of MDMA assisted therapies being able to be commercialized in the near future

Going deeper:

  • The majority of the new funding in Lykos Therapeutics will go towards preparing to commercialize MDMA assisted therapies, pending an official approval from the FDA
  • MAPS will still continue to maintain oversight of Lykos Therapeutics through having significant control of the voting power within the company

The intrigue:

  • Helena, the lead investor in this round, is a global problem solving organization which includes many notable members, such as Citadel’s Ken Griffin, Snapchat’s Evan Spiegel and legendary billionaire energy trader John Arnold

Discover the world's most disruptive early stage companies with 35,000+ investors.

The markets and trends that matter, made simple.

Join top talent at the world's most respected institutions, companies, and venture capital funds.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.